<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335257</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG 2005-2</org_study_id>
    <nct_id>NCT00335257</nct_id>
  </id_info>
  <brief_title>International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC)</brief_title>
  <official_title>International Active Surveillance Study of Women Taking Oral Contraceptives (INAS OC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the short- and long-term risks of a 24-day regimen of a
      drospirenone-containing oral contraceptive with the risks of established oral contraceptives
      in a study population that is representative for the actual users of the individual
      preparations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drospirenone is a novel progestogen with antiandrogenic and antimineralocorticoid properties.
      A large active post-marketing surveillance study has demonstrated that a 21-day regimen of
      3mg drospirenone and 30mcg ethinylestradiol can be used safely for oral contraception. This
      study investigates the risks of short and long-term use of a 24-day regimen of
      drospirenone/ethinylestradiol in comparison to established OCs in a study population that is
      representative of the actual users of the individual preparations.

      INAS-OC is a prospective, controlled, non-interventional cohort study with two study arms:
      OCs containing drospirenone and OCs containing any other progestogen. The study was started
      in the USA in April 2005 and was extended to several European countries in September 2008
      based on the launch status of the 24-day regimen. New users of an OC (starters, switchers
      without a pill intake break and recurrent users with a pill intake break [same or different
      OC]) are accrued by a network of prescribing physicians. Baseline and follow-up information
      are collected via a self-administered questionnaire. Data analysis will be based on
      life-table methods comparing the cohorts. All analyses will make allowance for confounding,
      using methods that will include multivariate techniques such as Cox regression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous Thromboembolism (VTE); Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs</measure>
    <time_frame>Within 60 months</time_frame>
    <description>Venous thromboembolism (VTE) hazard ratio for oral contraceptives containing both drospirenone (DRSP) and ethinylestradiol (EE) in a 24-day regimen or any oral contraceptive without DRSP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Thromboembolism (ATE), Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs</measure>
    <time_frame>Within 60 months</time_frame>
    <description>Arterial thromboembolism (ATE) in women using oral contraceptives containing both drospirenone (DRSP) and ethinylestradiol (EE) in a 24-day regimen or any oral contraceptive without DRSP. Cox regression analysis was not carried out. In accordance to the analysis plan, hazard ratios were only to be calculated if a minimum of 5 confirmed events were available in each of the comparison groups.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">85109</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Users of OCs containing DRSP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Users of OCs containing other progestins</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women using oral contraceptives
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First-ever OC users (&quot;starters&quot;)

          -  Women switching OC use without a pill intake break (&quot;switchers&quot;)

          -  Recurrent users with a pill intake break (&quot;recurrent users&quot;)

          -  Women willing to participate in the active surveillance

        Exclusion Criteria:

          -  Women who do not agree to participate

          -  Long-term users
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen C Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2006</study_first_posted>
  <results_first_submitted>November 6, 2014</results_first_submitted>
  <results_first_submitted_qc>November 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Juergen Dinger, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drospirenone</keyword>
  <keyword>Safety</keyword>
  <keyword>INAS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 91,474 patients were recruited for the INAS-OC study. Of these, 6,365 participants were excluded due to protocol violations.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>OC DRSP-24d</title>
          <description>OCs containing DRSP (Yaz®, 24 day regimen)</description>
        </group>
        <group group_id="P2">
          <title>OC DRSP-21d</title>
          <description>OCs containing DRSP (Yasmin®, 21 day regimen)</description>
        </group>
        <group group_id="P3">
          <title>OCs Non-DRSP</title>
          <description>Users of OCs containing other progestins</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15542"/>
                <participants group_id="P2" count="9377"/>
                <participants group_id="P3" count="60190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15542">Numbers completed refer to first follow-up. Individual follow-up ranged between 0.5 and 6.0 years.</participants>
                <participants group_id="P2" count="9377"/>
                <participants group_id="P3" count="60190">Numbers completed refer to first follow-up. Individual follow-up ranged between 0.5 and 6.0 years.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OC DRSP-24d</title>
          <description>OCs containing DRSP (Yaz®, 24 day regimen )</description>
        </group>
        <group group_id="B2">
          <title>OC DRSP-21d</title>
          <description>OCs containing DRSP (Yasmin®, 21 day regimen)</description>
        </group>
        <group group_id="B3">
          <title>OCs Non-DRSP</title>
          <description>Users of OCs containing other progestins</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15542"/>
            <count group_id="B2" value="9377"/>
            <count group_id="B3" value="60190"/>
            <count group_id="B4" value="85109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2054"/>
                    <measurement group_id="B2" value="1149"/>
                    <measurement group_id="B3" value="7582"/>
                    <measurement group_id="B4" value="10785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13488"/>
                    <measurement group_id="B2" value="8227"/>
                    <measurement group_id="B3" value="52608"/>
                    <measurement group_id="B4" value="74323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.21" spread="7.64"/>
                    <measurement group_id="B2" value="26.14" spread="7.48"/>
                    <measurement group_id="B3" value="26.34" spread="7.73"/>
                    <measurement group_id="B4" value="26.29" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15542"/>
                    <measurement group_id="B2" value="9377"/>
                    <measurement group_id="B3" value="60190"/>
                    <measurement group_id="B4" value="85109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="922"/>
                    <measurement group_id="B2" value="1438"/>
                    <measurement group_id="B3" value="11207"/>
                    <measurement group_id="B4" value="13567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10299"/>
                    <measurement group_id="B2" value="3978"/>
                    <measurement group_id="B3" value="37892"/>
                    <measurement group_id="B4" value="52169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="738"/>
                    <measurement group_id="B2" value="611"/>
                    <measurement group_id="B3" value="2945"/>
                    <measurement group_id="B4" value="4294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="371"/>
                    <measurement group_id="B4" value="948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1644"/>
                    <measurement group_id="B2" value="1427"/>
                    <measurement group_id="B3" value="2657"/>
                    <measurement group_id="B4" value="5728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1169"/>
                    <measurement group_id="B2" value="1457"/>
                    <measurement group_id="B3" value="3664"/>
                    <measurement group_id="B4" value="6290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="1454"/>
                    <measurement group_id="B4" value="2113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Venous Thromboembolism (VTE); Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs</title>
        <description>Venous thromboembolism (VTE) hazard ratio for oral contraceptives containing both drospirenone (DRSP) and ethinylestradiol (EE) in a 24-day regimen or any oral contraceptive without DRSP.</description>
        <time_frame>Within 60 months</time_frame>
        <population>Study participants that were not excluded due to protocol violation</population>
        <group_list>
          <group group_id="O1">
            <title>OC DRSP-24d</title>
            <description>24-day regimen of DRSP/EE</description>
          </group>
          <group group_id="O2">
            <title>OC DRSP-21d</title>
            <description>21-day regimen of DRSP/EE</description>
          </group>
          <group group_id="O3">
            <title>OCs Non-DRSP</title>
            <description>Users of OCs containing other progestins than DRSP</description>
          </group>
          <group group_id="O4">
            <title>NOHC</title>
            <description>Non-oral hormonal contraception (injections, implants, levonorgestrel-containing IUDs, or contraceptive patches)</description>
          </group>
          <group group_id="O5">
            <title>No Use</title>
            <description>No (hormonal) contraception at last contact</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Thromboembolism (VTE); Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs</title>
          <description>Venous thromboembolism (VTE) hazard ratio for oral contraceptives containing both drospirenone (DRSP) and ethinylestradiol (EE) in a 24-day regimen or any oral contraceptive without DRSP.</description>
          <population>Study participants that were not excluded due to protocol violation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7264"/>
                <count group_id="O2" value="5605"/>
                <count group_id="O3" value="39316"/>
                <count group_id="O4" value="4070"/>
                <count group_id="O5" value="28854"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tested null hypotheses: the VTE hazard ratio for DRSP(24d) vs. Non-DRSP is higher or equal to 2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on a non-inferiority test of two exponential survival curves.These calculations are based on the following assumptions: 1) one-sided α 0.025; 2) power (1-β) of 0.90; 3) VTE incidence rate of 9/10.000 WY and 4) non-inferiority limit hazard ratio of 2. Furthermore, a study of this size would exclude a threefold risk of ATE.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for age, BMI, duration of current use, family history of VTE</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arterial Thromboembolism (ATE), Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs</title>
        <description>Arterial thromboembolism (ATE) in women using oral contraceptives containing both drospirenone (DRSP) and ethinylestradiol (EE) in a 24-day regimen or any oral contraceptive without DRSP. Cox regression analysis was not carried out. In accordance to the analysis plan, hazard ratios were only to be calculated if a minimum of 5 confirmed events were available in each of the comparison groups.</description>
        <time_frame>Within 60 months</time_frame>
        <population>Study participants that were not excluded due to protocol violation</population>
        <group_list>
          <group group_id="O1">
            <title>OC DRSP-24d</title>
            <description>24-day regimen of DRSP/EE</description>
          </group>
          <group group_id="O2">
            <title>OC DRSP-21d</title>
            <description>21-day regimen of DRSP/EE</description>
          </group>
          <group group_id="O3">
            <title>OCs Non-DRSP</title>
            <description>Users of OCs containing other progestins</description>
          </group>
          <group group_id="O4">
            <title>NOHC</title>
            <description>Non-oral hormonal contraception (injections, implants, levonorgestrel-containing IUDs, or contraceptive patches)</description>
          </group>
          <group group_id="O5">
            <title>No Use</title>
            <description>No (hormonal) contraception</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Thromboembolism (ATE), Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs</title>
          <description>Arterial thromboembolism (ATE) in women using oral contraceptives containing both drospirenone (DRSP) and ethinylestradiol (EE) in a 24-day regimen or any oral contraceptive without DRSP. Cox regression analysis was not carried out. In accordance to the analysis plan, hazard ratios were only to be calculated if a minimum of 5 confirmed events were available in each of the comparison groups.</description>
          <population>Study participants that were not excluded due to protocol violation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7264"/>
                <count group_id="O2" value="5605"/>
                <count group_id="O3" value="39316"/>
                <count group_id="O4" value="4070"/>
                <count group_id="O5" value="28854"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of ATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>of which acute myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>of which ichemic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>of which transient ischemic attack (TIA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>of which peripheral ATE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events was collected over a time period of 5 years.</time_frame>
      <desc>Complete cohorts, as-treated population. All study participants were asked for adverse events at each follow-up. The total number of serious adverse events do not include 132 SAEs (due to data entry options), for which information on organ system is missing.</desc>
      <group_list>
        <group group_id="E1">
          <title>DRSP-24d</title>
          <description>24-day regimen of DRSP/EE</description>
        </group>
        <group group_id="E2">
          <title>DRSP-21d</title>
          <description>21-day regimen of DRSP/EE</description>
        </group>
        <group group_id="E3">
          <title>OCs Non-DRSP</title>
          <description>Users of OCs containing other progestins</description>
        </group>
        <group group_id="E4">
          <title>NOHC</title>
          <description>Non-oral hormonal contraception (injections, implants, levonorgestrel-containing IUDs, or patches)</description>
        </group>
        <group group_id="E5">
          <title>No Use</title>
          <description>No (hormonal) contraception)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="583" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="499" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="2740" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="254" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="1756" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the blood and blood-forming organs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular system</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="278" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="98" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine diseases</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive system</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="553" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="259" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious diseases</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="68" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, accidents, etc</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="383" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="136" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal system and connective tissue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms, malignant</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="28854"/>
              </event>
              <event>
                <sub_title>Neoplasms, benign</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, delivery and puerperium</sub_title>
                <description>SAEs, which occurred within 3 months after stop of hormonal contraceptive use, were attributed to the last OC/NOHC used by the women. Therefore, pregnancy related SAEs in OC/NOHC cohorts do not reflect unwanted pregnancies during OC/NOHC use.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="571" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric and neurological disorders</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="226" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="109" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary system</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="471" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="253" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="183" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7264"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5605"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39316"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4070"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28854"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Juergen Dinger, MD, PhD</name_or_title>
      <organization>Center for Epidemiology and Health Research, Germany</organization>
      <phone>0049(0)30 945 10120</phone>
      <email>dinger@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

